WYZGA MICHAEL S
Transaction: 02/26/2026
BUY
Change
+66,000
Price
$0.39
Filing
02/27/2026
Type
BUY
Mereo BioPharma Group plc
MREO • Biotechnology
$0.26
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$41.79M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 10.46Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:22 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.26
Change0.00%
Shares Out160.71M
Market Cap$41.79M
Enterprise Value$12.70M
52W Range0.20 - 2.37
Beta0.30
P/E-1.49
P/B1.46
P/FCF-1.65
EV/EBITDA-0.40
EV/FCF-0.50
Price$0.26
Change0.00%
Shares Out160.71M
Market Cap$41.79M
Enterprise Value$12.70M
52W Range0.20 - 2.37
Beta0.30
P/E-1.49
P/B1.46
P/FCF-1.65
EV/EBITDA-0.40
EV/FCF-0.50
Earnings Yield-67.22%
FCF Yield-60.66%
Dividend Yield0.00%
Gross Margin73.40%
Oper. Margin-76.51%
Profit Margin-83.76%
Debt/Eq0.00
Current Ratio10.46
Quick Ratio10.46
Target$3.25
Target Upside1150.00%
Target Median$2.50
Target Range0.50 - 8.00
Volume8.37M
Avg Volume2.70M
EPS Surprise-0.03
Investment DNA
How strong this company looks for long-term investors
35
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
55/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 10.46Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 8 analyst votes · 2026-09-04
75/100
Bullish
Bullish
5
Hold
2
Bearish
1
Price Target
2026-08-13
Low
$0.50
Mean
$3.25
Median
$2.50
High
$8.00
Insider Transactions
Recent executive and insider activity
Jenkins Annalisa
Transaction: 02/26/2026
BUY
Change
+66,000
Price
$0.39
Filing
02/27/2026
Type
BUY
Jenkins Annalisa
Transaction: 02/26/2026
BUY
Change
+106,848
Price
Not reported
Filing
02/27/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| WYZGA MICHAEL S | BUY | +66,000 | $0.39 | 02/26/2026 | 02/27/2026 |
| Jenkins Annalisa | BUY | +66,000 | $0.39 | 02/26/2026 | 02/27/2026 |
| Jenkins Annalisa | BUY | +106,848 | Not reported | 02/26/2026 | 02/27/2026 |
| PAKIANATHAN DEEPIKA | BUY | +66,000 | $0.39 | 02/26/2026 | 02/27/2026 |
| Bender Jeremy | BUY | +66,000 | $0.39 | 02/26/2026 | 02/27/2026 |
| Bender Jeremy | BUY | +117,533 | Not reported | 02/26/2026 | 02/27/2026 |
| Ekblom Anders | BUY | +66,000 | $0.39 | 02/26/2026 | 02/27/2026 |
| Ekblom Anders | BUY | +133,560 | Not reported | 02/26/2026 | 02/27/2026 |
| Shames Daniel | BUY | +66,000 | $0.39 | 02/26/2026 | 02/27/2026 |
| Shames Daniel | BUY | +96,163 | Not reported | 02/26/2026 | 02/27/2026 |
| Yoskowitz Marc J | BUY | +66,000 | $0.39 | 02/26/2026 | 02/27/2026 |
| Yoskowitz Marc J | BUY | +96,163 | Not reported | 02/26/2026 | 02/27/2026 |
| Jacquet Pierre | BUY | +66,000 | $0.39 | 02/26/2026 | 02/27/2026 |
| Jacquet Pierre | BUY | +106,848 | Not reported | 02/26/2026 | 02/27/2026 |
| Fox Christine Ann | BUY | +105,250 | $1.00 | 02/01/2026 | 02/02/2026 |
| Scots-Knight Denise | BUY | +345,000 | $1.00 | 02/01/2026 | 02/02/2026 |
| Sermon Charles | BUY | +105,250 | $1.00 | 02/01/2026 | 02/02/2026 |
| Hughes-Wilson Alexandra | BUY | +61,250 | $1.00 | 02/01/2026 | 02/02/2026 |
| Lewicki John A. | BUY | +46,637 | $1.00 | 02/01/2026 | 02/02/2026 |
| Jacquet Pierre | BUY | +15,243 | Not reported | 02/05/2025 | 02/06/2025 |